Published:
Psilocybe Allenii
"Allen's Psilocybe"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeAllenii-1_new-800x450.webp)
Scientific Classification
About
Psilocybe allenii, commonly known as Allen’s Psilocybe, is a potent psilocybin-containing mushroom native to the West Coast of North America, especially in California, Oregon, and Washington. It thrives in urban and landscaped areas, often fruiting in wood chips and mulch beds, and is noted for its strong psychoactive effects and vigorous growth in cultivation and the wild.
History
First formally described in 2012, Psilocybe allenii was named in honor of John W. Allen, a prolific ethnomycologist and psychonaut known for his contributions to psychedelic mushroom research. Although newly classified, it had been informally observed and consumed for years, often mistaken for P. cyanescens due to their similar habitat and appearance.
It has since become a favorite among foragers and cultivators for its robust flushes, moderate to high potency, and early fruiting season (often in autumn).
Overview
P. allenii has a convex to flat cap, ranging from caramel to chestnut brown when moist, with a hygrophanous (fading) quality as it dries. The cap typically spans 2–6 cm, and the stem is whitish with occasional blue bruising. It produces a dark purple-brown spore print.
Its psychoactive effects include strong visual patterning, euphoria, emotional release, and altered perception of time and space. Its potency, ease of identification, and abundance in human-modified environments make it one of the most reliably found wild psilocybin mushrooms in the western U.S.
Physical Characteristics
Caps:
Convex to broadly convex, sometimes with a low umbo, 1-4 cm wide, reddish-brown to yellowish-brown, fading to pale ochre when dry
Gills:
Adnate to adnexed, initially pale, becoming purplish-black with age
Psychoactive Effects
Euphoric
Describing intense feelings of happiness or excitement
Perceptual
The change in the way things are perceived, including changes in time perception, spatial perception, and perception of one's own body.
Pharmacology
Helps With
Depression
Relieves symptoms of depression, improving mood and outlook
Anxiety
Helps to alleviate feelings of worry, fear, and unease
Addiction
Helps to overcome addiction and substance abuse
PTSD
Helps to alleviate symptoms of post-traumatic stress disorder
OCD
Helps to alleviate symptoms of obsessive-compulsive disorder
ADD ADHD
Helps to alleviate symptoms of attention deficit disorder and attention deficit hyperactivity disorder
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines. A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
A feeling of discomfort in the stomach with an urge to vomit
Grow at Home
Start your cultivation journey with quality grow kits from verified vendors
Chemical Constituents
Medicinal Chemistry
Similar Species
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeStuntzii_new-400x400.webp)
Species: Psilocybe stuntzii
Edibility: Psychoactive
Key Differences: P. stuntzii typically has a more slender stem and a smaller cap compared to P. allenii.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeStuntzii_new-400x400.webp)
Species: Psilocybe stuntzii
Edibility: Psychoactive
Mushroom Ratings
5.0
(1)
Based on 1 Review
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
01/29/2025
Ruth Zota
References
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .
- Schindler, E. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. .
- Raval, N. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. .
- Kuypers, K. (2019). Psychedelic medicine: The biology underlying the persisting psychedelic effects. .